Evaxion announces business update and first quarter 2023 financial results

Copenhagen, denmark, may 31, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, announced today its first quarter 2023 financial results and provided a business update.

EVAX Ratings Summary

EVAX Quant Ranking